PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
148.49
P/E exceeding 1.5x Healthcare median of 1.59. Michael Burry would check for market euphoria. Scrutinize growth expectations.
No Data
No Data available this quarter, please select a different quarter.
-218.96
Negative equity while Healthcare median P/B is 1.63. Seth Klarman would investigate balance sheet restructuring potential.
530.93
P/FCF of 530.93 versus zero FCF in Healthcare. Walter Schloss would verify cash flow quality.
530.93
P/OCF of 530.93 versus zero operating cash flow in Healthcare. Walter Schloss would verify operational quality.
-218.96
Negative fair value while Healthcare median is 1.64. Seth Klarman would investigate valuation model issues.
0.17%
Earnings yield below 50% of Healthcare median of 0.45%. Jim Chanos would check for earnings sustainability risks.
0.19%
FCF yield of 0.19% versus zero FCF in Healthcare. Walter Schloss would verify cash flow quality.